The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Alnylam Pharmaceuticals Inc

Nasdaq: ALNY
Last

(U.S.) $41.57

Today's change0.00 0.00%
Updated December 2 4:00 PM EST. Delayed by at least 15 minutes.
 

Alnylam Pharmaceuticals Inc

Nasdaq: ALNY
Last

(U.S.) $41.57

Today's change0.00 0.00%
Updated December 2 4:00 PM EST. Delayed by at least 15 minutes.

Alnylam Pharmaceuticals Inc closed at (U.S.)$41.57.

Over the last five days, shares have lost 13.18% and are down 55.84% for the last year to date. This security has underperformed the S&P 500 by 65.29% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $41.57
  • High--
  • Low--
  • Bid / Ask(U.S.) $37.19 / (U.S.) $0.00
  • YTD % change-55.84%
  • Volume0
  • Average volume (10-day)1,537,715
  • Average volume (1-month)1,629,618
  • Average volume (3-month)1,300,991
  • 52-week range(U.S.) $31.38 to (U.S.) $109.10
  • Beta2.92
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$4.54
Updated December 2 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-1,041.16%

Although this company's net profit margin is negative, it is above the industry average and implies that Alnylam Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.00%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2016Q2/2016Q1/2016Q4/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015
Revenue14978
Total other revenue--------
Total revenue14978
Gross profit--------
Total cost of revenue--------
Total operating expense120101117100
Selling / general / administrative22182117
Research & development98839683
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-107-92-110-93
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-104-90-103-91
Income after tax-104-90-103-91
Income tax, total--000
Net income-104-90-103-91
Total adjustments to net income--------
Net income before extra. items-104-90-103-91
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-104-90-103-91
Inc. avail. to common incl. extra. items-104-90-103-91
Diluted net income-104-90-103-91
Dilution adjustment--------
Diluted weighted average shares86868585
Diluted EPS excluding extraordinary itemsvalue per share-1.21-1.05-1.21-1.07
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-1.21-1.05-1.21-1.07